Subscribe to unlock this article
Thanks for your support.
With deep expertise in the healthcare sector, scientist-turned-investor Robert Shore has launched Shorefox Partners to partner with healthcare business owners in the UK and Ireland, helping accelerate their companies to the next stage of growth while preserving team, culture, and values for long-term continuity. His search is backed primarily by European and North American investors, including Evolutiq, Relay Investments, ONEtoONE Asset Management, Legacy Partners, Victoriam Equity, Cabiedes Inversiones, Mazal Capital, Ed Butler, Luis Camilleri, Jonathan Ferrari, and Felix Leuschner.
From scientific research and data analysis to investment strategy and corporate finance, Robert is an accomplished healthcare professional who understands the unique challenges and opportunities facing owner-led businesses. He began his career in the telecommunications sector with Ericsson in Dublin before joining AdaptiveMobile, an Intel Capital–backed start-up. He then transitioned into life sciences through a strategy consulting internship at The Genome Analysis Centre, and went on to pursue an academic research career, holding positions as a Visiting Scientist at Trinity College Dublin, Postdoctoral Fellow at Massachusetts General Hospital, and Senior Postdoctoral Research Fellow at Harvard Medical School, where he led pioneering work on viral immunoresponses. Building on this scientific foundation, Robert moved into finance as a Biotech Equity Research Analyst at Redburn, covering advanced therapies and supporting IPO processes for biotech companies. He later advanced into investment management as Portfolio Manager at a Family Office, where he oversaw a $50M healthcare equity fund, before founding Longshore Partners, a healthcare specialist fund. Most recently, he was Senior Director at AstraZeneca, where he integrated financial insights into oncology strategy, shaping critical business decisions. He holds an MBA from the University of Cambridge and a PhD in Medicine from the University of St Andrews, and also served as a Trustee of Dementia Prevention UK.
Robert is particularly interested in UK & Ireland healthcare and services companies with EBITDA of at least £1.5M and enterprise value between £10–50M, characterized by high recurring revenues, strong cash flow, and defensible market positions. His focus areas include healthcare services (e.g., companies serving the biopharma ecosystem such as bioprocessing refrigeration, niche distribution, facilities management and maintenance, medical equipment, medical waste and contamination control), Contract Manufacturing Organizations (drug product manufacturing), Contract Research Organizations (research and clinical trial services), as well as roll-up–friendly subsectors such as audiology in the UK and ophthalmology in Ireland.
Legal: Marriott Harrison / Tax, Accounting and CoSec duties: Gerald Edelman
